Novel therapeutic role for dipeptidyl peptidase III in the treatment of hypertension

Hypertension

Volumn 68, Issue 3, 2016, Pages 630-641

  Pang, Xiaoling ^a,c   Shimizu, Akio ^a   Kurita, Souichi ^a   Zankov, Dimitar P ^a   Takeuchi, Keisuke ^a   Yasuda Yamahara, Mako ^a   Kume, Shinji ^a   Ishida, Tetsuo ^b   Ogita, Hisakazu ^a  

^a SHIGA UNIVERSITY OF MEDICAL SCIENCE   (Japan)

^b UNIVERSITY OF THE RYUKYUS   (Japan)

^c CHINA MEDICAL UNIVERSITY   (China)

Author keywords

acute kidney injury; angiotensin II; blood pressure; cardiomegaly; dipeptidyl peptidase III; kinetics

Indexed keywords

ALBUMIN; ANGIOTENSIN II; ANTIHYPERTENSIVE AGENT; CANDESARTAN; DIPEPTIDYL PEPTIDASE; DIPEPTIDYL PEPTIDASE III; NORADRENALIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; EXPERIMENTAL HYPERTENSION; HEART HEMODYNAMICS; HEART MUSCLE FIBROSIS; HEART RATE; HEART VENTRICLE HYPERTROPHY; HYPERTENSION; IMPLANTATION; IN VIVO STUDY; KIDNEY INJURY; MOUSE; NONHUMAN; OSMOTIC MINIPUMP; PRIORITY JOURNAL; PROTEIN URINE LEVEL; URINARY EXCRETION; ANALYSIS OF VARIANCE; ANIMAL; BLOOD PRESSURE; DISEASE MODEL; DRUG EFFECTS; ENZYMOLOGY; GLOMERULUS FILTRATION RATE; HEMODYNAMICS; INSTITUTE FOR CANCER RESEARCH MOUSE; METABOLISM; RANDOMIZATION; ROLE PLAYING; SENSITIVITY AND SPECIFICITY; TREATMENT OUTCOME;

ANALYSIS OF VARIANCE; ANGIOTENSIN II; ANIMALS; BLOOD PRESSURE; DIPEPTIDYL-PEPTIDASES AND TRIPEPTIDYL-PEPTIDASES; DISEASE MODELS, ANIMAL; GLOMERULAR FILTRATION RATE; HEART RATE; HEMODYNAMICS; HYPERTENSION; MICE; MICE, INBRED ICR; RANDOM ALLOCATION; ROLE; SENSITIVITY AND SPECIFICITY; TREATMENT OUTCOME;

EID: 84979996240     PISSN: 0194911X     EISSN: 15244563     Source Type: Journal    
DOI: 10.1161/HYPERTENSIONAHA.116.07357     Document Type: Article

References (53)

1. Rettig R, Ganten D, Lang RE, Unger T, The renin-Angiotensin system in the central control of blood pressure. Eur Heart J 1987 8 suppl B 129 132
2. Fitzsimons JT, Angiotensin, thirst, and sodium appetite. Physiol Rev 1998 78 583 686
3. Rong P, Wilkinson-Berka JL, Skinner SL, Control of renin secretion from adrenal gland in transgenic Ren-2 and normal rats. Mol Cell Endocrinol 2001 173 203 212
4. Kramkowski K, Mogielnicki A, Buczko W, The physiological significance of the alternative pathways of angiotensin II production. J Physiol Pharmacol 2006 57 529 539
5. Bader M, Peters J, Baltatu O, Müller DN, Luft FC, Ganten D, Tissue renin-Angiotensin systems: new insights from experimental animal models in hypertension research. J Mol Med (Berl) 2001 79 76 102
6. Roks A, Buikema H, Pinto YM, van Gilst WH, The renin-Angiotensin system and vascular function The role of angiotensin II, angiotensin-converting enzyme, and alternative conversion of angiotensin I. Heart Vessels 1997 Suppl 12 119 124
7. Dostal DE, Hunt RA, Kule CE, Bhat GJ, Karoor V, McWhinney CD, Baker KM, Molecular mechanisms of angiotensin II in modulating cardiac function: intracardiac effects and signal transduction pathways. J Mol Cell Cardiol 1997 29 2893 2902. doi: 10.1006/jmcc.1997.0524
8. Escobar E, Rodríguez-Reyna TS, Arrieta O, Sotelo J, Angiotensin II, cell proliferation and angiogenesis regulator: biologic and therapeutic implications in cancer. Curr Vasc Pharmacol 2004 2 385 399
9. Saxena PR, Interaction between the renin-Angiotensin-Aldosterone and sympathetic nervous systems. J Cardiovasc Pharmacol 1992 19 suppl 6 S80 S88
10. Zucker IH, Xiao L, Haack KK, The central renin-Angiotensin system and sympathetic nerve activity in chronic heart failure. Clin Sci (Lond) 2014 126 695 706. doi: 10.1042/CS20130294
11. Dupont AG, Brouwers S, Brain angiotensin peptides regulate sympathetic tone and blood pressure. J Hypertens 2010 28 1599 1610. doi: 10.1097/HJH.0b013e32833af3b2
12. Stegbauer J, Coffman TM, New insights into angiotensin receptor actions: from blood pressure to aging. Curr Opin Nephrol Hypertens 2011 20 84 88. doi: 10.1097/MNH.0b013e3283414d40
13. Moravski CJ, Kelly DJ, Cooper ME, Gilbert RE, Bertram JF, Shahinfar S, Skinner SL, Wilkinson-Berka JL, Retinal neovascularization is prevented by blockade of the renin-Angiotensin system. Hypertension 2000 36 1099 1104
14. Benigni A, Cassis P, Remuzzi G, Angiotensin II revisited: new roles in inflammation, immunology and aging. EMBO Mol Med 2010 2 247 257. doi: 10.1002/emmm.201000080
15. Donnelly R, Manning G, Angiotensin-converting enzyme inhibitors and coronary heart disease prevention. J Renin Angiotensin Aldosterone Syst 2007 8 13 22. doi: 10.3317/jraas.2007.002
16. Wright JW, Mizutani S, Harding JW, Pathways involved in the transition from hypertension to hypertrophy to heart failure. Treatment strategies. Heart Fail Rev 2008 13 367 375. doi: 10.1007/s10741-007-9060-z
17. Katragadda S, Arora RR, Role of angiotensin-converting enzyme inhibitors in vascular modulation: beyond the hypertensive effects. Am J Ther 2010 17 e11 e23. doi: 10.1097/MJT.0b013e31815addd9
18. Fukasawa K, Fukasawa KM, Iwamoto H, Hirose J, Harada M, The HELLGH motif of rat liver dipeptidyl peptidase III is involved in zinc coordination and the catalytic activity of the enzyme. Biochemistry 1999 38 8299 8303. doi: 10.1021/bi9904959
19. Ohkubo I, Li YH, Maeda T, Yamamoto Y, Yamane T, Du PG, Nishi K, Dipeptidyl peptidase III from rat liver cytosol: purification, molecular cloning and immunohistochemical localization. Biol Chem 1999 380 1421 1430. doi: 10.1515/BC.1999.182
20. Ellis S, Nuenke JM, Dipeptidyl arylamidase III of the pituitary. Purification and characterization. J Biol Chem 1967 242 4623 4629
21. Ohkubo I, Li Y, Maeda T, Yamamoto Y, Yamane T, Du PG, Nishi K, Molecular cloning and immunohistochemical localization of rat dipeptidyl peptidase III. Forensic Sci Int 2000 113 147 151
22. Bezerra GA, Dobrovetsky E, Viertlmayr R, Dong A, Binter A, Abramic M, Macheroux P, Dhe-Paganon S, Gruber K, Entropy-driven binding of opioid peptides induces a large domain motion in human dipeptidyl peptidase III. Proc Natl Acad Sci U S A 2012 109 6525 6530. doi: 10.1073/pnas.1118005109
23. Prajapati SC, Chauhan SS, Dipeptidyl peptidase III: a multifaceted oligopeptide N-end cutter. FEBS J 2011 278 3256 3276. doi: 10.1111/j.1742-4658.2011.08275.x
24. Abramić M, Schleuder D, Dolovcak L, Schröder W, Strupat K, Sagi D, Peter-Katalini J, Vitale L, Human and rat dipeptidyl peptidase III: biochemical and mass spectrometric arguments for similarities and differences. Biol Chem 2000 381 1233 1243. doi: 10.1515/BC.2000.151
25. Vanha-Perttula T, Dipeptidyl peptidase III and alanyl aminopeptidase in the human seminal plasma: origin and biochemical properties. Clin Chim Acta 1988 177 179 195
26. Shimamori Y, Watanabe Y, Fujimoto Y, Purification and characterization of dipeptidyl aminopeptidase III from human placenta. Chem Pharm Bull (Tokyo) 1986 34 3333 3340
27. Vitale L, Zubanović M, Abramić M, Properties and distribution of aminopeptidase and dipeptidyl aminopeptidase III of human erythrocytes. Acta Biol Med Ger 1981 40 1489 1495
28. Barsun M, Jajcanin N, Vukelić B, Spoljarić J, Abramić M, Human dipeptidyl peptidase III acts as a post-proline-cleaving enzyme on endomorphins. Biol Chem 2007 388 343 348. doi: 10.1515/BC.2007.039
29. Li YH, Maeda T, Yamane T, Ohkubo I, Alteration of rat dipeptidyl peptidase III by site-directed mutagenesis: cysteine(176) is a regulatory residue for the enzyme activity. Biochem Biophys Res Commun 2000 276 553 558. doi: 10.1006/bbrc.2000.3519
30. Gibbons GH, The pathophysiology of hypertension: the importance of angiotensin II in cardiovascular remodeling. Am J Hypertens 1998 11 11 pt 2 177S 181S
31. Brewster UC, Setaro JF, Perazella MA, The renin-Angiotensin-Aldosterone system: cardiorenal effects and implications for renal and cardiovascular disease states. Am J Med. Sci 2003 326 15 24
32. Struthers AD, MacDonald TM, Review of aldosterone-And angiotensin II-induced target organ damage and prevention. Cardiovasc Res 2004 61 663 670. doi: 10.1016/j.cardiores.2003.11.037
33. Iwanami J, Mogi M, Iwai M, Horiuchi M, Inhibition of the renin-Angiotensin system and target organ protection. Hypertens Res 2009 32 229 237. doi: 10.1038/hr.2009.5
34. Hoogwerf BJ, Renin-Angiotensin system blockade and cardiovascular and renal protection. Am J Cardiol 2010 105 1 suppl 30A 35A. doi: 10.1016/j.amjcard.2009.10.009
35. Ibrahim MM, Damasceno A, Hypertension in developing countries. Lancet 2012 380 611 619. doi: 10.1016/S0140-6736(12)60861-7
36. Perkovic V, Huxley R, Wu Y, Prabhakaran D, MacMahon S, The burden of blood pressure-related disease: a neglected priority for global health. Hypertension 2007 50 991 997. doi: 10.1161/HYPERTENSIONAHA.107.095497
37. Verdecchia P, Angeli F, Mazzotta G, Gentile G, Reboldi G, The renin angiotensin system in the development of cardiovascular disease: role of aliskiren in risk reduction. Vasc Health Risk Manag 2008 4 971 981
38. Jacoby DS, Rader DJ, Renin-Angiotensin system and atherothrombotic disease: from genes to treatment. Arch Intern Med 2003 163 1155 1164. doi: 10.1001/archinte.163.10.1155
39. Cicin-Sain L, Simaga S, Froebe A, Abramić M, Central aminopeptidase and serotonin system activities: possible relationship. Neuropeptides 2008 42 435 440. doi: 10.1016/j.npep.2008.04.007
40. Mazzocco C, Fukasawa KM, Auguste P, Puiroux J, Characterization of a functionally expressed dipeptidyl aminopeptidase III from Drosophila melanogaster. Eur J Biochem 2003 270 3074 3082
41. Lee CM, Snyder SH, Dipeptidyl-Aminopeptidase III of rat brain. Selective affinity for enkephalin and angiotensin. J Biol Chem 1982 257 12043 12050
42. Lan VT, Ito K, Ito S, Kawarasaki Y, Trp-Arg-Xaa tripeptides act as uncompetitive-Type inhibitors of human dipeptidyl peptidase IV. Peptides 2014 54 166 170. doi: 10.1016/j.peptides.2014.01.027
43. Baral PK, Jajcanin-Jozić N, Deller S, Macheroux P, Abramić M, Gruber K, The first structure of dipeptidyl-peptidase III provides insight into the catalytic mechanism and mode of substrate binding. J Biol Chem 2008 283 22316 22324. doi: 10.1074/jbc.M803522200
44. Balakumar P, Jagadeesh G, A century old renin-Angiotensin system still grows with endless possibilities: AT1 receptor signaling cascades in cardiovascular physiopathology. Cell Signal 2014 26 2147 2160. doi: 10.1016/j.cellsig.2014.06.011
45. Landmesser U, Cai H, Dikalov S, McCann L, Hwang J, Jo H, Holland SM, Harrison DG, Role of p47(phox) in vascular oxidative stress and hypertension caused by angiotensin II. Hypertension 2002 40 511 515
46. Murdoch CE, Alom-Ruiz SP, Wang M, Zhang M, Walker S, Yu B, Brewer A, Shah AM, Role of endothelial Nox2 NADPH oxidase in angiotensin II-induced hypertension and vasomotor dysfunction. Basic Res Cardiol 2011 106 527 538. doi: 10.1007/s00395-011-0179-7
47. Fagard RH, Celis H, Thijs L, Wouters S, Regression of left ventricular mass by antihypertensive treatment: a meta-Analysis of randomized comparative studies. Hypertension 2009 54 1084 1091. doi: 10.1161/HYPERTENSIONAHA.109.136655
48. Klingbeil AU, Schneider M, Martus P, Messerli FH, Schmieder RE, A meta-Analysis of the effects of treatment on left ventricular mass in essential hypertension. Am J Med 2003 115 41 46
49. Akioyamen L, Levine M, Sherifali D, O'Reilly D, Frankfurter C, Pullenayegum E, Goeree R, Tsoi B, Cardiovascular and cerebrovascular outcomes of long-Term angiotensin receptor blockade: meta-Analyses of trials in essential hypertension. J Am Soc Hypertens 2016 10 55 69.e1. doi: 10.1016/j.jash.2015.11.005
50. Strauss MH, Hall AS, The divergent cardiovascular effects of angiotensin converting enzyme inhibitors and angiotensin receptor blockers on myocardial infarction and death. Prog Cardiovasc Dis 2016 58 473 482. doi: 10.1016/j.pcad.2015.11.004
51. Costanzo P, Savarese G, Rosano G, Musella F, Casaretti L, Vassallo E, Paolillo S, Marsico F, Rengo G, Leosco D, Perrone-Filardi P, Left ventricular hypertrophy reduction and clinical events A meta-regression analysis of 14 studies in 12,809 hypertensive patients. Int J Cardiol 2013 167 2757 2764. doi: 10.1016/j.ijcard.2012.06.084
52. Nakao N, Yoshimura A, Morita H, Takada M, Kayano T, Ideura T, Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): a randomised controlled trial. Lancet 2003 361 117 124. doi: 10.1016/S0140-6736(03)12229-5
53. Yusuf S, Teo KK, Pogue J, Dyal L, Copland I, Schumacher H, Dagenais G, Sleight P, Anderson C, ONTARGET Investigators Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008 358 1547 1559. doi: 10.1056/NEJMoa0801317